US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE PHARMA GROUP

24.05

+0.36061.52%

Volume:2.56K

Turnover:61.97K

Market Cap:2.24B

PE:-12.15

High:24.64

Open:23.83

Low:23.83

Close:23.69

52wk High:48.45

52wk Low:17.56

Shares:93.33M

Float Shares:71.58M

Volume Ratio:1.63

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9795

EPS(LYR):-0.7356

ROE:-159.65%

ROA:-22.77%

PB:23.12

PE(LYR):-32.70

Loading ...

Overview Company News Filings

ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025

ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options

Hong Kong Stock: ASCENTAGE-B Rises Over 3%

HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Ascentage Pharma initiated with a Buy at Truist

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025

Ascentage Pharma Group International : Btig Initiates Coverage With Buy Rating; Target Price $50

THOMSON REUTERS

Ascentage Pharma initiated with a Buy at BTIG

Ascentage Pharma initiated with an Overweight at Piper Sandler

Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks

Ascentage Pharma Group International : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $48

THOMSON REUTERS

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025

ASCENTAGE-B (06855) to Showcase Multiple Clinical Advances of Olverembatinib (Nerlynx®), Lisaftoclax (Lisenla®), and APG-5918 at 2025 ASH Annual Meeting, Including One Oral Presentation

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

Global Major Conference ESMO Enters Countdown, High-Elasticity Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 2%! 3SBIO and ASCENTAGE-B Lead Strong Rally

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AAPG/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"ASCENTAGE PHARMA GROUP","latestPrice":24.0506,"timestamp":1773162588641,"preClose":23.69,"halted":0,"volume":2557,"delay":0,"changeRate":0.015221612494723428,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"Trading","change":0.3606,"latestTime":"03-10 13:33:17 EDT","open":23.83,"high":24.64,"low":23.83,"amount":61970.843434,"amplitude":0.034192,"askPrice":24.67,"askSize":2,"bidPrice":24.25,"bidSize":31,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773172800000},"marketStatusCode":2,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":23.69,"preHourTrading":{"tag":"盘前","latestPrice":23.7,"preClose":23.69,"latestTime":"08:00 EDT","volume":550,"amount":13085.0005,"timestamp":1773144011890,"change":0.01,"changeRate":0.000422,"amplitude":0.012664},"postHourTrading":{"tag":"盘后","latestPrice":23.69,"preClose":23.69,"latestTime":"18:44 EDT","volume":205,"amount":4764.45,"timestamp":1773096295219,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.627512},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":1.627512,"shares":93330405,"dividePrice":0,"high":24.64,"amplitude":0.034192,"preClose":23.69,"low":23.83,"week52Low":17.555,"pbRate":"23.12","psRate":"39.43","week52High":48.45,"institutionHeld":0,"latestPrice":24.0506,"committee":0.878788,"eps":-1.979486,"divideRate":0,"volume":2557,"delay":0,"ttmEps":-1.979486,"open":23.83,"prevYearClose":26.24,"prevWeekClose":23.14,"prevMonthClose":24.1,"prevQuarterClose":26.24,"fiveDayClose":21.64,"twentyDayClose":23.61,"sixtyDayClose":29.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"Pre-Market","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1765080000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-03-06","current":-11.967753,"percent":0.98556,"low":-76.454813,"twenty":-41.161756,"median":-28.176938,"eighty":-16.734267,"high":-11.627475,"avg":-31.259832,"sd":16.504942,"marketCap":2131116747.44},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83},{"date":"2026-02-20","current":-13.322258,"twenty":-42.10164,"median":-29.751262,"eighty":-17.934704,"marketCap":2235292402.77},{"date":"2026-02-27","current":-13.022247,"twenty":-41.475205,"median":-29.511221,"eighty":-17.157024,"marketCap":2206480506.48},{"date":"2026-03-06","current":-12.669019,"twenty":-41.161756,"median":-28.176938,"eighty":-16.734267,"marketCap":2131116747.44}],"updateTime":1773122019309},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151522256","title":"ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1151522256","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151522256?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:08","pubTimestamp":1764893308,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA-B (06855) announced that its self-developed Class 1 innovative drug, olverembatinib (brand name: Nerlynx®), has received approval from the U.S. Food and Drug Administration (FDA) and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALL","BK4107","LU1699723380.USD","BK4588","BK1161","EMA","BK1574","06855","BK4585","LU2355687059.USD","LU1571399168.USD","BK4533","BK4139","BK4134","III","AAPG","LU0985320562.USD","BK4081"],"gpt_icon":0},{"id":"2589550638","title":"Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2589550638","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589550638?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:00","pubTimestamp":1764892800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  04, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International(NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200415/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Olverembatinib-in-First-Line-Treatment-of-Ph-ALL-Cleared-by-US-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","EMA","LU1929549753.HKD","BK4134","AAPG","LU1571399168.USD","OS","ASH","LU0234570918.USD","BK4560","LU1244550221.USD","CSCO","IE00BDGV0183.EUR","CDE","CR","LU0868494708.USD","LU1244550577.SGD","BK4585","BK4579","LU0985320562.USD","LU0868494617.USD","III","LU1880398471.USD","ALL","BK4017","SG9999015986.USD","BK4020","BK4581","IE00BVYPNW00.USD","IE00BZ1G4Q59.USD","LU0234572021.USD","LU1599440770.SGD","LU2237443382.USD","LU2286300806.USD","LU1894683348.USD","LU2506952097.USD","LU0203347892.USD","IE00B3PB1722.GBP","LU0792757196.USD","BK4525","LU1066051225.USD","IE00BFMHRM44.USD","BK4161","LU1221951129.SGD","LU1674673428.USD","LU1221951046.USD","IE00BFXG1179.USD","BK4139","LU0348723411.USD"],"gpt_icon":0},{"id":"2588720594","title":"Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720594","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720594?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196956/0/en/Ascentage-Pharma-to-Host-Webcast-Highlighting-Key-Data-from-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HST","BK4181","AAPG","BK4585","BK4139","BK4218","ASH","BK4109","LU2463526074.USD"],"gpt_icon":0},{"id":"1195526525","title":"ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options","url":"https://stock-news.laohu8.com/highlight/detail?id=1195526525","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195526525?lang=en_us&edition=fundamental","pubTime":"2025-11-27 21:24","pubTimestamp":1764249856,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that, as of the date of this announcement, it has granted 1.3045 million restricted share units under the 2022 Restricted Share Unit Plan to 146 selected...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK1574","06855","BK4139","BK1161"],"gpt_icon":0},{"id":"1126789920","title":"Hong Kong Stock: ASCENTAGE-B Rises Over 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126789920","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126789920?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:21","pubTimestamp":1764127283,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855.HK) surged more than 3% in Hong Kong trading. At the time of writing, the stock was up 3.04% to HK$64.35, with a turnover of HK$46.05 million.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK4139","BK1574","BK1161","AAPG"],"gpt_icon":0},{"id":"1182587677","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1182587677","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182587677?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:00","pubTimestamp":1764126017,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06855","AAPG","BK1574","BK4139"],"gpt_icon":0},{"id":"2586341936","title":"Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341936","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586341936?lang=en_us&edition=fundamental","pubTime":"2025-11-25 08:00","pubTimestamp":1764028800,"startTime":"0","endTime":"0","summary":"Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov.  24, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3193993/0/en/Ascentage-Pharma-Announces-Publication-of-Olverembatinib-Phase-Ib-Safety-Efficacy-and-Novel-Mechanism-Data-in-Gastrointestinal-Stromal-Tumors-in-Nature-s-Signal-Transduction-and-Ta.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","AAPG","LU1223083913.SGD","LU1223082196.USD","ORR","CDE","LU1223082519.USD","BK4139"],"gpt_icon":0},{"id":"2585246494","title":"Ascentage Pharma initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2585246494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585246494?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:30","pubTimestamp":1763987446,"startTime":"0","endTime":"0","summary":"Truist analyst Gregory Renza initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $51 price target The company’s Lisaftoclax is diff...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2584949009","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949009","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949009?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Nov.  19, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190863/0/en/Ascentage-Pharma-to-Participate-in-Three-Upcoming-Investor-Conferences-in-December-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2582878259","title":"Ascentage Pharma Group International : Btig Initiates Coverage With Buy Rating; Target Price $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2582878259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582878259?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:55","pubTimestamp":1762775715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nFWN3WM1E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK1574","AAPG","BK1161","06855"],"gpt_icon":0},{"id":"2582820923","title":"Ascentage Pharma initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2582820923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582820923?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:10","pubTimestamp":1762773025,"startTime":"0","endTime":"0","summary":"BTIG initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $50 price target The firm says Ascentage has a “validated” apoptosis-targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2581274016","title":"Ascentage Pharma initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2581274016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581274016?lang=en_us&edition=fundamental","pubTime":"2025-11-05 18:05","pubTimestamp":1762337111,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin initiated coverage of Ascentage Pharma (AAPG) with an Overweight rating and $48 price target The company’s two app...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascentage-pharma-initiated-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2581747406","title":"Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2581747406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581747406?lang=en_us&edition=fundamental","pubTime":"2025-11-05 17:46","pubTimestamp":1762335969,"startTime":"0","endTime":"0","summary":"Biren Amin, an analyst from Piper Sandler, has initiated a new Buy rating on Ascentage Pharma Group International Unsponsored ADR (AAPG). Biren Ami...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-potential-of-ascentage-pharmas-key-assets-olverembatinib-and-lisaftoclax-drive-buy-rating-amidst-risks-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-potential-of-ascentage-pharmas-key-assets-olverembatinib-and-lisaftoclax-drive-buy-rating-amidst-risks-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2581744875","title":"Ascentage Pharma Group International : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $48","url":"https://stock-news.laohu8.com/highlight/detail?id=2581744875","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581744875?lang=en_us&edition=fundamental","pubTime":"2025-11-05 17:02","pubTimestamp":1762333347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WH0U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06855","BK1161","BK1574","AAPG","BK4139"],"gpt_icon":0},{"id":"2580936275","title":"Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580936275","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580936275?lang=en_us&edition=fundamental","pubTime":"2025-11-04 09:10","pubTimestamp":1762218600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Nov.  03, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3179927/0/en/Ascentage-Pharma-to-Present-Data-from-Two-Clinical-Studies-for-Bcl-2-Inhibitor-Lisaftoclax-Including-an-Oral-Report-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","AAPG","BK4533","BK4139","BK4225","BK4161","ORR","ALL","LU2463526074.USD","ASH","BK4203","LU0985320562.USD","HR","BK4097","BK4585","OS","BK4107","BK4109","BK4588","LU1571399168.USD","LU1699723380.USD","TLS","LU2355687059.USD"],"gpt_icon":0},{"id":"2580275931","title":"Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580275931","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580275931?lang=en_us&edition=fundamental","pubTime":"2025-11-04 09:10","pubTimestamp":1762218600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Nov.  03, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3179926/0/en/Ascentage-Pharma-to-Present-Data-from-Multiple-Studies-of-Olverembatinib-Including-the-First-Dataset-from-POLARIS-1-Study-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4533","LU2463526074.USD","ALL","LU0985320562.USD","BK4588","BK4139","BK4585","AAPG","BK4107","BK4109","LU2355687059.USD","BK4161","CR","ASH","LU1699723380.USD","CHR","BK4077"],"gpt_icon":0},{"id":"1114777561","title":"ASCENTAGE-B (06855) to Showcase Multiple Clinical Advances of Olverembatinib (Nerlynx®), Lisaftoclax (Lisenla®), and APG-5918 at 2025 ASH Annual Meeting, Including One Oral Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=1114777561","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114777561?lang=en_us&edition=fundamental","pubTime":"2025-11-04 08:26","pubTimestamp":1762215986,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) announced that multiple clinical and preclinical advancements of its three drug candidates—olverembatinib (brand name: Nerlynx®), lisaftoclax (brand name: Lisenla®; R&D code:...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","LU2125909759.SGD","BK4139","06855","LU2463526074.USD","AAPG","ASH","BK4129","BK1574","LU2125909916.SGD","APG","LU1923622291.USD","BK1161"],"gpt_icon":0},{"id":"2579156566","title":"Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579156566","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579156566?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:00","pubTimestamp":1761782400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Oct.  29, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3176999/0/en/Ascentage-Pharma-to-Participate-in-Two-Upcoming-Investor-Conferences-in-November-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"1149520534","title":"Global Major Conference ESMO Enters Countdown, High-Elasticity Hong Kong Stock Connect Innovative Drug ETF (520880) Surges 2%! 3SBIO and ASCENTAGE-B Lead Strong Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1149520534","media":"Deep News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149520534?lang=en_us&edition=fundamental","pubTime":"2025-10-15 14:42","pubTimestamp":1760510537,"startTime":"0","endTime":"0","summary":"On the afternoon of October 15th, the Hong Kong Stock Connect innovative drug sector continued to rally, with ASCENTAGE-B leading gains of nearly 6%, while CStone Pharmaceuticals-B, Innocare...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AAPG","BK1583","520880","01530","BK1593","BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2573957371","title":"Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573957371","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573957371?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:00","pubTimestamp":1759838400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, Oct.  07, 2025  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/07/3162459/0/en/Ascentage-Pharma-to-Participate-in-Three-Upcoming-Investor-Conferences-in-October-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}